Patents by Inventor Shalom Goldberg

Shalom Goldberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240391849
    Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.
    Type: Application
    Filed: June 6, 2024
    Publication date: November 28, 2024
    Inventors: Vadim Dudkin, Shalom Goldberg, Joseph Erhardt, Rhys Salter, Theresa McDevitt
  • Publication number: 20240384002
    Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.
    Type: Application
    Filed: August 2, 2024
    Publication date: November 21, 2024
    Inventors: Vadim Dudkin, Shalom Goldberg, Michael J. McCauley, Kristen Wiley
  • Patent number: 12084475
    Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: September 10, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Vadim Dudkin, Shalom Goldberg, Michael J. McCauley, Kristen Wiley
  • Publication number: 20240270870
    Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.
    Type: Application
    Filed: April 10, 2024
    Publication date: August 15, 2024
    Inventors: Shalom Goldberg, Donna Klein, Neeraj Kohli, Theresa Marie McDevitt, Steven J. Orcutt
  • Patent number: 12054534
    Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: August 6, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms
  • Publication number: 20240238461
    Abstract: The present invention is directed to compounds and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and immunoconjugates, radioimmunoconjugates thereof, in the treatment of neuroplastic diseases or disorders.
    Type: Application
    Filed: November 21, 2023
    Publication date: July 18, 2024
    Inventors: Rhys Salter, Vadim Y. Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
  • Patent number: 11987641
    Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: May 21, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Shalom Goldberg, Donna Klein, Neeraj Kohli, Theresa Marie McDevitt, Steven J. Orcutt
  • Patent number: 11702475
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: July 18, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Shalom Goldberg, Steven Jacobs, Tricia Lin, Karyn O'Neil
  • Publication number: 20230131727
    Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.
    Type: Application
    Filed: August 25, 2022
    Publication date: April 27, 2023
    Inventors: Shalom GOLDBERG, Donna KLEIN, Neeraj KOHLI, Theresa Marie MCDEVITT, Steven J. ORCUTT
  • Publication number: 20230122503
    Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.
    Type: Application
    Filed: August 25, 2022
    Publication date: April 20, 2023
    Inventors: Shalom GOLDBERG, et al., Donna KLEIN, Neeraj KOHLI, Theresa Marie MCDEVITT, Steven J. ORCUTT
  • Publication number: 20230110178
    Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.
    Type: Application
    Filed: June 30, 2022
    Publication date: April 13, 2023
    Inventors: RHYS SALTER, VADIM DUDKIN, FENGBIN SONG, WEI ZHANG, SHALOM GOLDBERG, JOHN KEITH
  • Patent number: 11576986
    Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: February 14, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Rhys Salter, Vadim Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
  • Publication number: 20220143231
    Abstract: The present invention is directed to compounds and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and immunoconjugates, radioimmunoconjugates thereof, in the treatment of neuroplastic diseases or disorders.
    Type: Application
    Filed: November 9, 2021
    Publication date: May 12, 2022
    Inventors: Rhys Salter, Vadim Y. Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
  • Publication number: 20210388085
    Abstract: Engineered antibodies useful for site-specific conjugation by a transglutaminase are described. Also described are methods of site-specific conjugation of the antibodies, the site-specifically conjugated antibodies, and pharmaceutical compositions and uses related to the site-specifically conjugated antibodies.
    Type: Application
    Filed: May 19, 2021
    Publication date: December 16, 2021
    Inventors: Vadim Dudkin, Shalom Goldberg, Michael J. McCauley, Kristen Wiley, Rebecca Wissner
  • Publication number: 20210363177
    Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.
    Type: Application
    Filed: May 19, 2021
    Publication date: November 25, 2021
    Inventors: Vadim Dudkin, Shalom Goldberg, Michael J. McCauley, Kristen Wiley
  • Publication number: 20210301025
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Application
    Filed: May 28, 2021
    Publication date: September 30, 2021
    Inventors: Shalom GOLDBERG, Steven Jacobs, Tricia Lin, Karyn O'Neil
  • Patent number: 11072663
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 27, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Shalom Goldberg, Steven Jacobs, Tricia Lin, Karyn O'Neil
  • Publication number: 20210147510
    Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Application
    Filed: October 13, 2020
    Publication date: May 20, 2021
    Inventors: Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms
  • Publication number: 20210017099
    Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.
    Type: Application
    Filed: December 17, 2018
    Publication date: January 21, 2021
    Inventors: Vadim Dudkin, Shalom Goldberg, Joseph Erhardt, Rhys Salter, Theresa McDevitt
  • Patent number: 10844111
    Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: November 24, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms